Updated on 24 May 2012
Mr Roberts: You are correct. China is a huge market with many opportunities. SeerPharma is in discussions with some groups in China and looking at the pluses and minuses of establishing our training programs there. We believe there are similar opportunities there as in India. The difficulty in China as compared to India is, of course, the language. We see India as a better short-term opportunity because we can essentially take our existing offerings into India with very little reworking.
What are the future plans of the company?
Mr Roberts: SeerPharma intends to build on its reputation as Asia Pacific's premier quality assurance and compliance consultancy. To maintain this reputation, we need to increase our presence in emerging life sciences markets, particularly in India, China and South Korea. It is our intention to capitalize on the expansion of the life sciences industry in these markets. Our future focus will be on developing relationships with partners in each of these markets.